← All verticals

Edition 04  ·  July 2026

OTC & Consumer Health Intelligence

OTC & Consumer Health
Intelligence

25 products and technologies tracked across four therapeutic segments plus regulatory/market access. Claim landscape, reformulation signals, Rx-to-OTC pipeline, and competitive brand moves mapped monthly.

July 2026
01 Trend Radar

25 OTC products and formats. Four segments plus regulatory/market access. Evidence, maturity, and velocity mapped.

0 active red alerts 02 Monthly Pulse

Top five OTC signals this month. Ranked by consultant relevance.

Edition 04  ·  July 2026 03 Intelligence

Nine white space opportunities. Eight brands mapped. Monograph reform analysis.

Updated July 2026 04 Alerts

0 red  ·  2 amber  ·  2 green. Sorted by urgency.

2 monitoring alerts

Radar snapshot

25
Products tracked
4
Fringe signals
5
Segments

Highest velocity signals this month

Bemotrizinol: FDA finalizes the first new US sunscreen active in two decades. Market entry begins August 9, 2026.
Oral phenylephrine: final order still unpublished as the 2026 cold season approaches. Reformulation plans should assume removal proceeds.
GLP-1 companion nutrition: legacy OTC brands are relabeling SKUs faster than clinical evidence supports the claims.
OMUFA II: five-year monograph fee reauthorization through FY2030 locks in a durable order-request pathway.

Current alerts

AmberOral phenylephrine final order pending
AmberGLP-1 companion product claims substantiation gap
SignalBemotrizinol final order cleared, market entry August 9, 2026
SignalOMUFA II funding secured through FY2030

This edition

4 new radar entries added: bemotrizinol, oral phenylephrine removal, GLP-1 companion nutrition, OMUFA II reauthorization
0 new red alerts. Phenylephrine sits at amber, not red, since no final order has published. 2 new amber, 2 new green
3 white space opportunities added: phenylephrine SKU risk audit, GLP-1 claims framework, bemotrizinol reformulation timing